Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 90,301,432
  • Shares Outstanding, K 1,103,390
  • Annual Sales, $ 21,222 M
  • Annual Income, $ 2,738 M
  • 36-Month Beta 0.35
  • Price/Sales 4.27
  • Price/Cash Flow 17.34
  • Price/Book 6.43

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.77 +1.32%
on 07/25/17
85.53 -4.31%
on 07/24/17
-2.44 (-2.90%)
since 06/26/17
3-Month
76.85 +6.49%
on 05/22/17
85.53 -4.31%
on 07/24/17
+0.88 (+1.09%)
since 04/26/17
52-Week
64.18 +27.52%
on 11/23/16
86.72 -5.63%
on 04/05/17
-0.25 (-0.30%)
since 07/26/16

Most Recent Stories

More News
Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline

Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?

MRK : 61.80 (-0.90%)
LLY : 81.84 (-0.43%)
INCY : 137.19 (+2.72%)
PFE : 32.89 (-0.63%)
Featured Company News - Eli Lilly and Nektar Announce Agreement to Co-Develop NKTR-358, the Self-Administered Injection for a Number of Autoimmune Disease

LONDON, UK / ACCESSWIRE / July 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Nektar Therapeutics (NASDAQ: NKTR) ("Nektar"), following which we...

LLY : 81.84 (-0.43%)
NKTR : 23.12 (-0.47%)
3 Buy-Ranked Stocks That Just Crushed Earnings

These earnings reports not only demonstrate the past quarter???s solid performance, but they also preview its financial outlook over its next operational quarter.

TROW : 84.92 (+1.30%)
CAT : 113.52 (-0.89%)
LLY : 81.84 (-0.43%)
Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK

We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.

JNJ : 130.95 (-0.71%)
LLY : 81.84 (-0.43%)
VRTX : 163.42 (+0.90%)
NVS : 84.85 (+0.77%)
GILD : 74.19 (+0.61%)
GSK : 40.85 (-2.65%)
BIIB : 295.61 (+4.47%)
Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed

Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares....

LLY : 81.84 (-0.43%)
INCY : 137.19 (+2.72%)
SNY : 48.02 (-0.10%)
BIIB : 295.61 (+4.47%)
Lilly (LLY) Tops Q2 Earnings & Sales, Ups View, Stock Falls

Lilly beat estimates for both sales and earnings and raised its 2017 outlook. However, it said the NDA resubmission for its rheumatoid arthritis drug baricitinib will not occur this year.

LLY : 81.84 (-0.43%)
Bioengineered Protein Drugs Market Worth US$336.9 Billion by 2025: Increasing Drugs in Phase III of Clinical Trials to Boost the Market

Some of the prominent participants in the global bioengineered protein drugs market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Amgen, Inc., Bayer AG, Merck & Co., Inc., Dr. Reddy's Laboratories...

BAYRY : 130.5700 (+0.43%)
ABT : 50.40 (-0.85%)
JNJ : 130.95 (-0.71%)
MRK : 61.80 (-0.90%)
LLY : 81.84 (-0.43%)
NVS : 84.85 (+0.77%)
AMGN : 175.89 (-2.76%)
Accelerator Corporation Announces Series A Financing in Rodeo Therapeutics to Focus on Small-Molecule Regenerative Therapies

Accelerator Corporation, a leading life science investment and management firm, today announced a $5.9 million Series A financing in Rodeo Therapeutics Corporation, a company developing...

JNJ : 130.95 (-0.71%)
LLY : 81.84 (-0.43%)
CGIX : 3.75 (unch)
Hasbro and Hibbett sink as WebMD and Nektar climb

NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday:

HIBB : 14.65 (+3.53%)
CALM : 37.50 (+1.21%)
LLY : 81.84 (-0.43%)
SGMS : 39.00 (+2.63%)
ITW : 140.07 (-1.12%)
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN

Three pharma giants are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.

JNJ : 130.95 (-0.71%)
LLY : 81.84 (-0.43%)
NVS : 84.85 (+0.77%)
AMGN : 175.89 (-2.76%)
BIIB : 295.61 (+4.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research...

See More

Support & Resistance

2nd Resistance Point 82.43
1st Resistance Point 82.13
Last Price 81.84
1st Support Level 81.29
2nd Support Level 80.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.